hackint0sh/New-Dataset huggingface dataset:
nctId: NCT06339164 id: ObGynEASC006 briefTitle: Breech Delivery Skills. Resident Learning Program acronym: Breech overallStatus: NOT_YET_RECRUITING date: 2024-04-15 date: 2024-05-15 date: 2024-06-30 date: 2024-04-01 date: 2024-04-01 name: G. d'Annunzio University class: OTHER briefSummary: Breech delivery is one of the mail topic in emergency obstetrics for Italian Board of Obstetrics and Gynecology. Formal frontal lecture and digital learning represent nowadays the two typical learning methods. A bedside evaluation it's not feasible due to rarity of such emergency, due to the common senior physicians involvement when it occurs, and due to medico-legal risks. Mannequin scenario represents the best way of skill evaluation conditions: Breech Presentation; Before Labor studyType: OBSERVATIONAL observationalModel: CASE_CONTROL timePerspective: CROSS_SECTIONAL count: 20 type: ESTIMATED name: skills and learning quality in breech delivery measure: Skills capacities measure: Skills capacities measure: learning qualities sex: ALL minimumAge: 24 Years maximumAge: 38 Years stdAges: ADULT facility: Claudio Celentano city: Pescara state: PE zip: 65100 country: Italy lat: 42.4584 lon: 14.20283 hasResults: False
nctId: NCT06339151 id: TUH multiple dexamethasone TKA briefTitle: Comparing Single Dose and Multiple Dose of Dexamethasone Post TKA overallStatus: RECRUITING date: 2024-03-23 date: 2025-10-31 date: 2025-10-31 date: 2024-04-01 date: 2024-04-01 name: Thammasat University Hospital class: OTHER briefSummary: The goal of this clinical trial is to investigate the efficacy of single dose and double dose of dexamethasone after primary total knee replacement.
Participants will \[describe the main tasks participants will be asked to do, interventions they'll be given and use bullets if it is more than 2 items\]. conditions: Osteo Arthritis Knee conditions: Pain, Postoperative studyType: INTERVENTIONAL phases: NA allocation: RANDOMIZED interventionModel: PARALLEL primaryPurpose: TREATMENT masking: QUADRUPLE whoMasked: PARTICIPANT whoMasked: CARE_PROVIDER whoMasked: INVESTIGATOR whoMasked: OUTCOMES_ASSESSOR count: 120 type: ESTIMATED name: Dexamethasone before surgery name: Dexamethasone before and 12 hours after surgery name: Dexamethasone before and 24 hours after surgery measure: Pain at rest and motion measure: Nausea and vomiting measure: Morphine consumption measure: Blood sugar level measure: CRP level measure: Range of motion measure: Length of hospital stay measure: Complication sex: ALL minimumAge: 50 Years maximumAge: 85 Years stdAges: ADULT stdAges: OLDER_ADULT facility: Thammasat University Hospital status: RECRUITING city: Khlong Luang state: Pathum Thani zip: 12120 country: Thailand name: Yot Tanariyakul, M.D. role: CONTACT phone: 6683930257 email: y.tanariyakul@gmail.com name: Yot Tanariyakul, M.D. role: PRINCIPAL_INVESTIGATOR name: Piya Pinsornsak, M.D. role: PRINCIPAL_INVESTIGATOR lat: 14.06467 lon: 100.64578 hasResults: False
nctId: NCT06339138 id: 17-010944 id: NCI-2024-00971 type: REGISTRY domain: CTRP (Clinical Trial Reporting Program) id: 17-010944 type: OTHER domain: Mayo Clinic in Rochester briefTitle: Identification of Novel High Quality Methylated DNA Markers in Renal Tumors: Whole Methylome Discovery, Tissue Validation, and Feasibility Testing In Blood and Urine, The INQUIRE Study overallStatus: RECRUITING date: 2018-02-20 date: 2027-01-31 date: 2027-01-31 date: 2024-04-01 date: 2024-04-01 name: Mayo Clinic class: OTHER briefSummary: This study is being done to collect blood, tissue and urine samples to identify a novel high quality methylated DNA marker in patients with renal tumors. conditions: Chromophobe Renal Cell Carcinoma conditions: Clear Cell Papillary Renal Tumor conditions: Clear Cell Renal Cell Carcinoma conditions: Kidney Oncocytoma conditions: Papillary Renal Cell Carcinoma conditions: Urothelial Carcinoma studyType: OBSERVATIONAL observationalModel: CASE_CONTROL timePerspective: CROSS_SECTIONAL count: 874 type: ESTIMATED name: Non-Interventional Study measure: Identify novel methylated DNA markers in tissue for malignant renal and urothelial tumors sex: ALL minimumAge: 18 Years stdAges: ADULT stdAges: OLDER_ADULT facility: Mayo Clinic in Rochester status: RECRUITING city: Rochester state: Minnesota zip: 55905 country: United States name: Clinical Trials Referral Office role: CONTACT phone: 855-776-0015 email: mayocliniccancerstudies@mayo.edu name: John C. Cheville, M.D. role: PRINCIPAL_INVESTIGATOR name: John B. Kisiel, M.D. role: PRINCIPAL_INVESTIGATOR lat: 44.02163 lon: -92.4699 hasResults: False
nctId: NCT06339125 id: 2023p003637 briefTitle: Predictive Analytics and Computer Visualization Enhances Patient Safety to Prevent Falls overallStatus: NOT_YET_RECRUITING date: 2024-05 date: 2025-05 date: 2025-07 date: 2024-04-01 date: 2024-04-01 name: Massachusetts General Hospital class: OTHER name: Crico name: Inspiren Inc name: RGI Informatics LLC briefSummary: Annually, in the United States there are 700,000 - 1,000,000 inpatient falls reported, and one-third of patients sustain an injury. The average estimated cost per fall is $6,694, resulting in over $1.4 -1.9 billion dollars in losses each year (AHRQ, 2017). This study aims to compare the impact of different fall prevention strategies on the rate of occurrence of falls and falls with injury in an academic medical center on three adult medical units. While maintaining the usual standard of care for fall prevention, each unit will add one of the following: (1) use of a fall risk alert to nurses using an algorithm based on electronic health record data or (2) computerized camera visualization or (3) a combination of both. conditions: Falls and Falls With Injury studyType: INTERVENTIONAL phases: NA allocation: NON_RANDOMIZED interventionModel: PARALLEL interventionModelDescription: An observational cohort, mixed-methods study design will be conducted to determine the impact and effectiveness of usual care and three different fall prevention strategies that exceed the standard of care on three inpatient units at MGH over one year. Unit 1 will employ streaming analytics and the MGH algorithm only, Unit 2 will employee Inspiren's AUGI computer visualization only and Unit 3 will employ the combined streaming analytic/MGH algorithm and Inspiren's AUGI device. Unit 4, the control unit, will serve as an internal comparison group from the same institution. In addition to the study interventions all four units will continue to maintain usual MGH evidence-based practice, standards of care for fall prevention. primaryPurpose: SUPPORTIVE_CARE masking: NONE count: 4500 type: ESTIMATED name: Fall prevention algorithm name: Inspiren camera visualization measure: Falls measure: Falls with injury measure: Nurse perceptions measure: Nurse perceptions sex: ALL minimumAge: 18 Years stdAges: ADULT stdAges: OLDER_ADULT hasResults: False
nctId: NCT06339112 id: 2024/10 briefTitle: The Effect of Playing With a Toy Nebulizer and Watching Cartoons on the Fear and Anxiety on Children overallStatus: NOT_YET_RECRUITING date: 2024-06-01 date: 2024-10-01 date: 2024-12-01 date: 2024-04-01 date: 2024-04-01 name: Tarsus University class: OTHER briefSummary: This research was planned as a randomized controlled experimental type to determine the effect of playing with a toy nebulizer and watching cartoons on children's fear and physiological parameters in 3-6 year old children who were administered inhaler medication. The population of the study, planned as a randomized controlled experimental study, will consist of 4-6 year old children who apply to Tarsus State Hospital pediatric services and receive inhaler treatment. According to the power analysis performed for the sample size, the power of the sample was calculated with the G\*Power 3.1 program, in line with the literature (Durak 2019; Özsamuri 2020). While the amount of Type I error was 0.05 and the power of the test was 0.95 (α= 0.05, 1-β= 0.95), the minimal sample size was calculated as 105 children (35 children in each group). Considering the possible losses from the sample for any reason during the study period, it was planned to increase the number of samples by 10% and include 38 children in the study and control groups. Child Information Form, Fear Assessment Scale and Child Anxiety Scale-State Scale will be used to collect data. conditions: Fear conditions: Anxiety conditions: Inhalant Use studyType: INTERVENTIONAL phases: NA allocation: RANDOMIZED interventionModel: PARALLEL interventionModelDescription: A randomized controlled experimental study primaryPurpose: OTHER masking: NONE count: 114 type: ESTIMATED name: Playing with toy nebulizer name: Cartoon measure: fear measure: anxiety sex: ALL minimumAge: 4 Years maximumAge: 6 Years stdAges: CHILD facility: Tarsus State Hospital city: Mersin country: Turkey lat: 36.79526 lon: 34.61792 hasResults: False
nctId: NCT06339099 id: P.T.REC/012/002489 briefTitle: Loaded Gait Training on Gross Motor Function in Cerebral Palsy overallStatus: COMPLETED date: 2023-02-26 date: 2023-10-15 date: 2024-03-15 date: 2024-04-01 date: 2024-04-01 name: Cairo University class: OTHER briefSummary: A randomized controlled trial aimed to evaluate the additional effect loaded gait training to conventional physical therapy program on gross motor function and the knee extensors strength in children with bilateral spastic cerebral palsy. Children were divided randomly into two equal groups. The control group received a conventional physical therapy program, while the intervention group received the same program plus loaded gait training. Gross motor functions and knee extensor strength were measured. conditions: Cerebral Palsy studyType: INTERVENTIONAL phases: NA allocation: RANDOMIZED interventionModel: PARALLEL interventionModelDescription: Children were randomly assigned into two equal groups. primaryPurpose: TREATMENT masking: DOUBLE maskingDescription: Double blinding. Parents were also blinded. whoMasked: PARTICIPANT whoMasked: OUTCOMES_ASSESSOR count: 52 type: ACTUAL name: Conventional physical therapy program name: Loaded gait training measure: Gross motor function measure: knee extensor strength sex: ALL minimumAge: 5 Years maximumAge: 7 Years stdAges: CHILD facility: Faculty of Physical Therapy, Cairo University city: Giza state: Cairo zip: 12613 country: Egypt lat: 30.00808 lon: 31.21093 hasResults: False
nctId: NCT06339086 id: BPR-201-I-III-01 briefTitle: Efficacy and Safety of Semaglutide Injection in Subjects With Type 2 Diabetes overallStatus: NOT_YET_RECRUITING date: 2024-04 date: 2025-08-30 date: 2025-12-30 date: 2024-04-01 date: 2024-04-01 name: Chengdu Brilliant Pharmaceutical Co., Ltd. class: INDUSTRY briefSummary: The goal of this clinical trial is to evaluate the similarities in efficacy and safety of semaglutide injection and Ozempic® in patients with type 2 diabetes who have poor glycemic control after metformin treatment.
Researchers will compare the outcomes of semaglutide and Ozempic® group to see if the efficacy, safety, pharmacokinetics, and immunogenicity of them are similar. conditions: Type 2 Diabetes Mellitus studyType: INTERVENTIONAL phases: PHASE3 allocation: RANDOMIZED interventionModel: PARALLEL primaryPurpose: TREATMENT masking: NONE count: 478 type: ESTIMATED name: Semaglutide Injection name: Semaglutide Injection(Ozempic®) name: Metformin measure: Change in HbA1c measure: Change in HbA1c measure: Change in FPG measure: Proportion of participants who achieved HbA1c<7.0%，HbA1c≤6.5% measure: Proportion of participants who achieved HbA1c<7.0%，HbA1c≤6.5% with no hypoglycemic event measure: Change in Body Weight measure: Proportion of participants with Weight Loss≥5%, ≥10% and ≥15% measure: Change in Diastolic and Systolic Blood Pressure measure: Changes in Blood Lipids measure: Incidence and severity of Adverse Events sex: ALL minimumAge: 18 Years maximumAge: 75 Years stdAges: ADULT stdAges: OLDER_ADULT hasResults: False
nctId: NCT06339073 id: 2021NZKY-045-01 briefTitle: CT-based Model for Predicting Prolonged Weaning in Patients With Abdominal Trauma overallStatus: COMPLETED date: 2023-10-01 date: 2023-12-15 date: 2024-02-05 date: 2024-04-01 date: 2024-04-01 name: Jinling Hospital, China class: OTHER briefSummary: Critically ill patients often require tracheal intubation for mechanical ventilation, and timely weaning is crucial for airway management and reducing complications. However, there is currently a lack of an effective tool to predict weaning time in critically ill patients. This retrospective study established an effective nomogram model for predicting the time of weaning from mechanical ventilation in abdominal trauma patients by considering multiple perspectives. The model has been validated and demonstrated good performance in terms of discrimination, calibration, and clinical utility. Moreover, the model can effectively predict the prognosis of critically ill patients. The findings of this study have important implications for guiding respiratory management in clinically critically ill patients, particularly trauma patients. conditions: Wounds and Injuries conditions: Ventilation Therapy; Complications studyType: OBSERVATIONAL observationalModel: COHORT timePerspective: RETROSPECTIVE count: 1023 type: ACTUAL name: mechanical ventilation measure: Prolonged mechanical ventilation sex: ALL minimumAge: 18 Years stdAges: ADULT stdAges: OLDER_ADULT facility: the General Surgical Department of Jinling Hospital city: Nanjing state: Jiangsu zip: 210002 country: China lat: 32.06167 lon: 118.77778 hasResults: False
nctId: NCT06339060 id: RTS-022 briefTitle: An Organ Preservation Strategies After Chemoradiotherapy Combined With Immunotherapy for Esophageal Cancer (PALACE3). acronym: PALACE3 overallStatus: NOT_YET_RECRUITING date: 2024-05-01 date: 2028-03-01 date: 2028-03-01 date: 2024-04-01 date: 2024-04-01 name: Ruijin Hospital class: OTHER briefSummary: Patients with locally advanced esophageal squamous cell carcinoma will randomly assigned to receive neoadjuvant chemo-radiotherapy combined with immunotherapy post organ preservation strategy (experimental group) or neoadjuvant chemo-radiotherapy followed by surgery (control group).
The 3-year overall survival rate is the primary outcome. conditions: Esophageal Cancer studyType: INTERVENTIONAL phases: PHASE3 allocation: RANDOMIZED interventionModel: PARALLEL primaryPurpose: TREATMENT masking: NONE maskingDescription: Randomize patients who meet the inclusion criteria Grouping, randomly assigned to the experimental group in a 1:1 ratio (organ preservation strategy after neoadjuvant chemotherapy combined with immunotherapy) And the control group (limited time for esophageal cancer radical surgery after neoadjuvant radiotherapy and chemotherapy) count: 356 type: ESTIMATED name: Experimental: Arm 1 Organ preservation name: Active Comparator: Arm 2 Surgery measure: 3-year overall survival rate sex: ALL minimumAge: 18 Years maximumAge: 75 Years stdAges: ADULT stdAges: OLDER_ADULT hasResults: False
nctId: NCT06339047 id: 2024/09 briefTitle: The Effect of Projector Kaleidoscope and Cartoons on Anxiety, Fear, and Pain in Children overallStatus: NOT_YET_RECRUITING date: 2024-06-01 date: 2024-10-01 date: 2024-12-01 date: 2024-04-01 date: 2024-04-01 name: Tarsus University class: OTHER briefSummary: The research will be conducted with children hospitalized in Tarsus State Hospital Children's Clinics and who meet the sampling criteria.
In collecting research data; the Introductory Information Form, Child Anxiety Scale, Child Fear Scale, Wong-Baker Pain Scale and Vital Signs Follow-up Form will be used. conditions: Anxiety and Fear conditions: Pain conditions: Surgery studyType: INTERVENTIONAL phases: NA allocation: RANDOMIZED interventionModel: PARALLEL interventionModelDescription: A randomized controlled experimental study primaryPurpose: OTHER masking: NONE count: 90 type: ESTIMATED name: Projector Kaleidoscope name: Cartoon measure: Anxiety measure: Fear measure: Pain after surgery sex: ALL minimumAge: 4 Years maximumAge: 10 Years stdAges: CHILD facility: Tarsus State Hospital city: Mersin country: Turkey lat: 36.79526 lon: 34.61792 hasResults: False
nctId: NCT06339034 id: STUDY briefTitle: Repurposing Lithium for Parkinson's Disease: a RCT overallStatus: NOT_YET_RECRUITING date: 2024-06 date: 2025-08 date: 2025-10 date: 2024-04-01 date: 2024-04-01 name: State University of New York at Buffalo class: OTHER name: The Cure Parkinson's Trust briefSummary: This study will examine the effects of lithium 20mg/day compared to placebo on MRI and blood-based biomarkers among 20 early-stage Parkinson's disease patients. conditions: Parkinson Disease studyType: INTERVENTIONAL phases: PHASE1 phases: PHASE2 allocation: RANDOMIZED interventionModel: PARALLEL interventionModelDescription: Double-blind, placebo-controlled primaryPurpose: TREATMENT masking: QUADRUPLE whoMasked: PARTICIPANT whoMasked: CARE_PROVIDER whoMasked: INVESTIGATOR whoMasked: OUTCOMES_ASSESSOR count: 20 type: ESTIMATED name: Lithium name: Placebo measure: MRI-derived free water (FW) levels. measure: Peripheral blood mononuclear cell (PBMC) nuclear receptor-related 1 protein (Nurr1) mRNA expression measure: Serum neurofilament light chain (NfL) measure: PBMC superoxide dismutase type-1 (SOD-1) mRNA expression measure: PBMC pS9/total glycogen synthase kinase-3B (GSK-3B) ratio measure: PBMC pThr308 and pS473/total protein kinase B (Akt) ratios measure: Serum interleukin-6 measure: Serum glial fibrillary acidic protein (GFAP) measure: Movement Disorder Society-Unified Parkinson's Disease Rating Scale (MDS-UPDRS) Part III (Motor Examination) measure: Montreal Cognitive Assessment (MoCA) measure: Parkinson's Anxiety Scale measure: Geriatric Depression Scale-15 measure: Fatigue Severity Scale measure: Insomnia Severity Index measure: Parkinson's Disease Questionnaire-8 measure: Levodopa equivalent daily dose (LEDD) measure: Adverse events sex: ALL minimumAge: 40 Years maximumAge: 80 Years stdAges: ADULT stdAges: OLDER_ADULT facility: UBMD Neurology city: Williamsville state: New York zip: 14221 country: United States name: Thomas Guttuso, MD role: CONTACT phone: 716-932-6080 email: tguttuso@buffalo.edu name: Amelia Cheney role: CONTACT email: acheney4@buffalo.edu name: Thomas Guttuso, MD role: PRINCIPAL_INVESTIGATOR lat: 42.96395 lon: -78.73781 hasResults: False
nctId: NCT06339021 id: DAPT-OCT briefTitle: OCT or Angiography Guided De-escalation of DAPT overallStatus: NOT_YET_RECRUITING date: 2024-04-01 date: 2026-12-01 date: 2026-12-01 date: 2024-04-01 date: 2024-04-01 name: Shenyang Northern Hospital class: OTHER briefSummary: Optical coherence tomography (OCT) offers a high-resolution intravascular imaging modality to accurately assess vessel and lumen geometry and identify the hallmark of a culprit lesion including plaque disruption and thrombus. In addition, the incorporation of the MLD MAX algorithm into daily practice guides an efficient and easily-memorable workflow for optimized OCT-guided percutaneous coronary intervention (PCI) with drug-eluting stents (DES). Regarding the antithrombotic therapy after revascularization, the 2023 ESC guidelines recommend the P2Y12 receptor inhibitor de-escalation (i.e. switching from ticagrelor to clopidogrel) in ACS patients may be considered as an alternative strategy to the default treatment regimen in order to reduce the risk of bleeding events.
Based on the above conclusions, we designed a single-center, prospective, randomized controlled, exploratory study trial to evaluate whether the utility of OCT for guiding PCI with DES followed by antiplatelet de-escalation therapy could further reduce the stent-induced intimal hyperplasia of STEMI patients after stent implantation. conditions: Optical Coherence Tomography conditions: Dual Antiplatelet Therapy conditions: Antiplatelet De-escalation conditions: Neointimal Coverage conditions: ST Elevation Myocardial Infarction studyType: INTERVENTIONAL phases: EARLY_PHASE1 allocation: RANDOMIZED interventionModel: PARALLEL primaryPurpose: TREATMENT masking: QUADRUPLE whoMasked: PARTICIPANT whoMasked: CARE_PROVIDER whoMasked: INVESTIGATOR whoMasked: OUTCOMES_ASSESSOR count: 80 type: ESTIMATED name: OCT-guided PCI name: Conventional angiography-based PCI name: DAPT de-escalation name: default DAPT regimen measure: Neointimal thickness after DES implantation measure: Major adverse cardiovascular and cerebrovascular events (MACCE) measure: BARC types 2-5 bleeding measure: In-stent thrombosis sex: ALL minimumAge: 18 Years maximumAge: 75 Years stdAges: ADULT stdAges: OLDER_ADULT facility: Northern Hospital city: Shenyang state: Liaoning country: China name: Yaling Han, Dr role: CONTACT phone: +86-24-28897313 email: cardiology@163.com name: Yaling Han, MD role: PRINCIPAL_INVESTIGATOR name: Yang Li, MD role: SUB_INVESTIGATOR name: Yi Li, MD role: SUB_INVESTIGATOR lat: 41.79222 lon: 123.43278 hasResults: False
nctId: NCT06338995 id: 18790 id: J2T-MC-KGBU type: OTHER domain: Eli Lilly and Company id: 2023-508760-29-00 type: OTHER domain: EU CT Number briefTitle: A Study of Lebrikizumab (LY3650150) in Adult Participants With Chronic Rhinosinusitis and Nasal Polyps Treated With Intranasal Corticosteroids (CONTRAST-NP) overallStatus: NOT_YET_RECRUITING date: 2024-04-10 date: 2025-11-22 date: 2026-10-25 date: 2024-04-01 date: 2024-04-01 name: Eli Lilly and Company class: INDUSTRY briefSummary: The main purpose of this study is to evaluate the efficacy and safety of lebrikizumab in adult participants with chronic rhinosinusitis and nasal polyps treated with intranasal corticosteroids. The study will last about 18 months. conditions: Chronic Rhinosinusitis With Nasal Polyps (CRSwNP) studyType: INTERVENTIONAL phases: PHASE3 allocation: RANDOMIZED interventionModel: PARALLEL interventionModelDescription: Randomized, double-blind, parallel group, placebo controlled primaryPurpose: TREATMENT masking: QUADRUPLE maskingDescription: Double-blind whoMasked: PARTICIPANT whoMasked: CARE_PROVIDER whoMasked: INVESTIGATOR whoMasked: OUTCOMES_ASSESSOR count: 510 type: ESTIMATED name: LY3650150 name: Placebo name: Standard therapy for INCS measure: Mean Change From Baseline (CFBL) in Participant Reported Nasal Congestion Score (NCS) Severity measure: Mean CFBL in Endoscopic Nasal Polyp Score (NPS) measure: Mean change in Opacification of Sinuses Measured by the Lund Mackay score (LMK) measure: Mean change in Forced Expiratory Volume in 1 Second (FEV1) measure: Mean CFBL in Severity of Loss of Smell measure: Mean CFBL in Postnasal Drip sex: ALL minimumAge: 18 Years stdAges: ADULT stdAges: OLDER_ADULT facility: South Louisiana Ear, Nose, Throat & Facial Plastic Surgery - PPDS city: Mandeville state: Louisiana zip: 70448 country: United States name: James Connolly role: PRINCIPAL_INVESTIGATOR lat: 30.35825 lon: -90.06563 facility: Ear Nose and Throat Associates of Texas PA city: McKinney state: Texas zip: 75070-5735 country: United States name: Dale Ehmer, Jr. role: PRINCIPAL_INVESTIGATOR lat: 33.19762 lon: -96.61527 facility: Alamo ENT Associates city: San Antonio state: Texas zip: 78258-3227 country: United States role: CONTACT phone: 210-545-0404 name: Jeffrey Rosenbloom role: PRINCIPAL_INVESTIGATOR lat: 29.42412 lon: -98.49363 facility: Richmond Ear Nose and Throat city: Richmond state: Virginia zip: 23235 country: United States role: CONTACT phone: 804-622-3768 name: Michael Armstrong role: PRINCIPAL_INVESTIGATOR lat: 37.55376 lon: -77.46026 hasResults: False
nctId: NCT06338982 id: N-20230059 briefTitle: Fracture Pattern Following Bilateral Sagittal Split Osteotomy With or Without Impacted Third Molars overallStatus: NOT_YET_RECRUITING date: 2024-03-30 date: 2029-10-31 date: 2030-10-31 date: 2024-04-01 date: 2024-04-01 name: Kimie Bols Østergaard class: OTHER briefSummary: The goal of this clinical trial is to investigate the hypothesis that there are none difference in the treatment result of orthognathic surgery on the lower jaw, with interoperative wisdom tooth removal rather than preoperative wisdom tooth removal. In patients with severe dental malocclusion combined with a dentofacial deformity. The main question it aims to answer are: